Astatine-211 based radionuclide therapy: Current clinical trial landscape.

ABSTRACT: Astatine-211 (²¹¹At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

SUBMITTER: Albertsson P 

PROVIDER: S-EPMC9859440 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature